Article in Molecules (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
7 authors.
Qinyi HeNational & Local Joint Engineering Laboratory of Animal Peptide Drug Development, Peptide and Small Molecule Drug R&D Platform of Furong Laboratory, College of Life Sciences, Hunan Normal University, Changsha 410081, China.
Ling LuoNational & Local Joint Engineering Laboratory of Animal Peptide Drug Development, Peptide and Small Molecule Drug R&D Platform of Furong Laboratory, College of Life Sciences, Hunan Normal University, Changsha 410081, China.
Dezhao ZhangNational & Local Joint Engineering Laboratory of Animal Peptide Drug Development, Peptide and Small Molecule Drug R&D Platform of Furong Laboratory, College of Life Sciences, Hunan Normal University, Changsha 410081, China.
Wenxiang ZhouHunan Engineering Research Center of Lotus Deep Processing and Nutritional Health Sciences, School of Life and Health Sciences, Hunan University of Science and Technology, Xiangtan 411201, China.
Ningning BaiHunan Engineering Research Center of Lotus Deep Processing and Nutritional Health Sciences, School of Life and Health Sciences, Hunan University of Science and Technology, Xiangtan 411201, China.
Canwei DuHunan Engineering Research Center of Lotus Deep Processing and Nutritional Health Sciences, School of Life and Health Sciences, Hunan University of Science and Technology, Xiangtan 411201, China.ORCID 0000-0003-4722-9403
Songlian LiDepartment of Breast Surgery, Second Affiliated Hospital of Hunan University of Chinese Medicine, Changsha 410036, China.
Funding
Hunan Provincial Natural Science Foundation 2023JJ40494Hunan Provincial Natural Science Foundation 2024JJ8216Hunan Provincial Natural Science Foundation 2026JJ80156
6 · The paper itself
Abstract
Breast cancer represents a persistent global health burden, marked by extensive molecular heterogeneity and frequent therapeutic resistance in aggressive subtypes, particularly triple-negative breast cancer (TNBC). These clinical challenges underscore the urgency for alternative therapeutic strategies. Bioactive alkaloids isolated from
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Molecular Mechanisms Underlying the Anti-Tumor Activity of Lotus-Derived Alkaloids in Breast Cancer. · full record | OpenQuestion